Clinical Trials

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603791 2026-05-22

Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.

252 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05546866 2026-05-13

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

51 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07329322 2026-05-11

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03778229 2026-04-23

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT07295821 2026-04-08

NSCLC

60 enrolled

Lung Neoplasms

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05801029 2026-03-20

OSTARA

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05526755 2026-03-04

TARGET

188 enrolled

Stage II-IIIB Non-small Cell Lung Carcinoma

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02442349 2026-01-09

AURA17

171 enrolled 14 charts

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07229729 2025-12-01

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05215951 2025-10-15

MINOVA

Phase 2 Terminated

4 enrolled 9 charts

Lung Neoplasms

NCT05880706 2025-09-19

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

198 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06574347 2025-05-21

KYLIN-2

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498986 2025-05-07

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06895928 2025-04-22

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

400 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05948813 2024-11-21

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

420 enrolled

CNS

Brain Neoplasms

NCT02094261 2024-11-06

AURA2

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03239340 2024-10-21

ELIOS

154 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06391944 2024-04-30

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

161 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05132777 2021-11-24

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Phase 2 Unknown

155 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

32 enrolled 11 charts